BRAF and melanoma: We observed that PLX4032 treatment results in a substantial increase of MITF ChIP-seq peaks over LTR5_Hs elements (123 out of 615 loci were bound under PLX4032 treatment but only 19 were bound in the control cells) (Figure 2D), suggesting that MITF binds LTR5_Hs loci, preferentially in BRAF inhibited melanoma cells.